Andrzej Zeglen
Infectious Disease · Evansville, INNPI 1578092805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $788 and has fallen 59.8% since, to $317 in 2025.
Across 134 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$423
- Gilead$358
- AbbVie$334
- Merck$273
- Shionogi Inc$244
- Astellas Pharma US Inc$177
- plus $829 from 18 others
What the payments were for
- Food & beverage$2,50095%
- Education$1405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 22 | $423 |
| Gilead | 21 | $358 |
| AbbVie | 18 | $334 |
| Merck | 15 | $273 |
| Shionogi Inc | 9 | $244 |
| Astellas Pharma US Inc | 8 | $177 |
| Viiv Healthcare Company | 6 | $143 |
| Melinta Therapeutics, LLC | 7 | $124 |
| La Jolla Pharmaceutical Company | 4 | $107 |
| Amgen | 4 | $76 |
| Johnson & Johnson | 2 | $54 |
| Mylan Specialty L.p. | 2 | $40 |
| Calliditas Therapeutics US Inc. | 2 | $40 |
| Novartis | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| AstraZeneca | 1 | $25 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Pfizer | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Oxford Immunotec USA Inc | 1 | $15 |
| Novo Nordisk | 1 | $13 |
How this compares
$2,640 in reported general payments places this provider in the 85th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 47 | $81,182 |
| ErtapenemErtapenem Sodium | 16 | $11,670 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 34 | $9,405 |
| Cefazolin Sodium | 30 | $2,041 |
| CeftriaxoneCeftriaxone Sodium | 14 | $1,993 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $1,685 |
| Doxycycline Monohydrate | 17 | $597 |
| Cephalexin | 15 | $270 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Evansville
- Maneesha AhluwaliaEvansville$1K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
- Darron BrownIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.